Article Sidebar
Views PDF: 180
TREATMENT APPROACH WITH IMMUNOTHERAPY IN METASTATIC COLORECTAL CANCER: A CASE REPORT
Main Article Content
Abstract
the global healthcare system and is the third leading cause of cancer-related deaths worldwide. The treatment of metastatic colorectal cancer has seen substantial advancements. Various treatment methods such as chemotherapy, targeted therapies, and immunotherapy have extended the survival time for patients. Approximately 5% of metastatic colorectal cancer cases exhibit high microsatellite instability (MSI-H) due to deficiencies in DNA mismatch repair (dMMR). Typically, patients with MSI-H/dMMR metastatic colorectal cancer respond poorly to conventional chemotherapy and have a poor prognosis. Studies have shown that MSI-H/dMMR tumors can achieve durable responses when treated with immunotherapy. We administered the immunotherapy drug Pembrolizumab to a patient who had failed systemic chemotherapy at Cho Ray Hospital, achieving an impressive response
Article Details
Keywords
Colorectal cancer, Immunotherapy, Microsatellite instability-high, DNA mismatch repair deficiency.
References
2. Chen ML, Chen JY, Hu J, et al. Comparison of microsatellite status detection methods in colorectal carcinoma. Int J Clin Exp Pathol. 2018;11(3):1431-1438.
3. Ooki, A., Shinozaki, E., & Yamaguchi, K. Immunotherapy in colorectal cancer: current and future strategies. Journal of the Anus, Rectum and Colon, 2021;5(1):11-24.
4. Haanen, J. B. A. G., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C.,... & Larkin, J. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022;33(12):1217-1238.
5. André T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999;17(11):3560-3568.
6. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523.
7. Yin J, Cohen R, Jin Z, et al. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. J Natl Cancer Inst 2021; 113:1705.